Pyridoxamine: The many virtues of a maillard reaction inhibitor

Annals of the New York Academy of Sciences

Volumn 1043, Issue , 2005, Pages 807-816

  Voziyan, Paul A ^a   Hudson, Billy G ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Advanced glycation end products; Diabetic complications; Kidney stones; Pyridoxamine; Reactive carbonyl compounds; Reactive oxygen species

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ANTIOXIDANT; CARBONYL DERIVATIVE; EDETIC ACID; GLYOXAL; HYDROXYL RADICAL; METHYLGLYOXAL; NITRIC OXIDE; PENTETIC ACID; PYRIDOXAMINE; REACTIVE OXYGEN METABOLITE; STREPTOZOCIN;

ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLYCATION; HUMAN; NEPHROLITHIASIS; NONHUMAN; OXIDATIVE STRESS; PROTEIN GLYCOSYLATION; RENAL PROTECTION;

EID: 23744514571     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1333.093     Document Type: Conference Paper

References (68)

1. SNELL, E.E. 1944. The vitamin activities of "pyridoxal" and "pyridoxamine." J. Biol. Chem. 154: 313-314.
2. HARRIS, S.A., D. HEYL & K. FOLKERS. 1944. The structure and synthesis of pyridoxamine and pyridoxal. J. Biol. Chem. 154: 315-316.
3. 6 group. V. The reversible interconversion of pyridoxal and pyridoxamine by transamination reactions. J. Am. Chem. Soc. 67: 194-197.
4. BRAUNSTEIN, A.E. 1939. The enzyme system of transamination, its mode of action and biological significance. Nature 143: 609-610.
5. COHEN, P.P. 1940. Transamination with purified enzyme preparations (transaminase). J. Biol. Chem. 136: 565-584.
6. BRAUNSTEIN, A.E. & M.M. SHEMYAKIN. 1952. Theory of processes of amino acid metabolism that are catalyzed by pyridoxal enzymes. Dokl. Akad. Nauk SSSR 85: 1115-1118.
7. 6-catalyzed reactions. J. Am. Chem. Soc. 76: 648-652.
8. METZLER, D.E. 1979. Tautomerism in pyridoxal phosphate and in enzymatic catalysis. Adv. Enzymol. Relat. Areas Mol. Biol. 50: 1-40.
9. 6 group and related 3-hydroxypyridine derivatives. J. Am. Chem. Soc. 77: 2431-2437.
10. WILLIAMS, V.R. & J.B. NEILANDS. 1954. Apparent ionization constants, spectral properties and metal chelation of the cotransaminases and related compounds. Arch. Biochem. 53: 56-70.
11. GUSTAFSON, R.L. & A.E. MARTELL. 1957. Stabilities of metal chelates of pyridoxamine. Arch. Biochem. Biophys. 68: 485-498.
12. 6). Inorg. Chim. Acta 46: 199-203.
13. DAWSON, R.M.C., D.C. ELLIOTT, W.H. ELLIOTT & K.M. JONES. 1986. Data for Biochemical Research. Clarendon Press. Oxford.
14. MIDDLETON, H.M. 1986. Intestinal hydrolysis of pyridoxal 5′-phosphate in vitro and in vivo in the rat. Effect of protein binding and pH. Gastroenterology 91: 343-350.
15. 6 metabolism by human liver. Ann. N.Y. Acad. Sci. 585: 110-117.
16. SAKURAI, T., T. ASAKURA, A. MIZUNO & M. MATSUDA. 1992. Absorption and metabolism of pyridoxamine in mice. II. Transformation of pyridoxamine to pyridoxal in intestinal tissues. J. Nutr. Sci. Vitaminol. (Tokyo) 38: 227-233.
17. SAMPSON, D.A. & D.K. O'CONNOR. 1989. Analysis of B-6 vitamers and pyridoxic acid in plasma, tissues and urine using high performance liquid chromatography. Nutr. Res. 9: 259-272.
18. DEGENHARDT, T.P. et al. 2002. Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int. 61: 939-950.
19. BROWNLEE, M. 1995. Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med. 46: 223-234.
20. COLACO, C.A. & C.R. HARRINGTON. 1994. Glycation: a pathological modification in neuropathies?: a hypothesis. Neuroreport 5: 859-861.
21. THORPE, S.R. & J.W. BAYNES. 1996. Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 9: 69-77.
22. BOOTH, A.A., R.G. KHALIFAH & B.G. HUDSON. 1996. Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: comparison with aminoguanidine. Biochem. Biophys. Res. Commun. 220: 113-119.
23. KHALIFAH, R.G. et al. 1996. Kinetics of nonenzymatic glycation of ribonuclease A leading to advanced glycation end products. Paradoxical inhibition by ribose leads to facile isolation of protein intermediate for rapid post-Amadori studies. Biochemistry 35: 4645-4654.
24. BOOTH, A.A., R.G. KHALIFAH, P. TODD & B.G. HUDSON. 1997. In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs). Novel inhibition of post-Amadori glycation pathways. J. Biol. Chem. 272: 5430-5437.
25. KHALIFAH, R.G., J.W. BAYNES & B.G. HUDSON. 1999. Amadorins: novel post-Amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commun. 257: 251-258.
26. VOZIYAN, P.A. et al. 2003. Modification of proteins in vitro by physiological levels of glucose: pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ions. J. Biol. Chem. 278: 46616-46624.
27. PRICE, D.L., P.M. RHETT, S.R. THORPE & J.W. BAYNES. 2001. Chelating activity of advanced glycation end-product inhibitors. J. Biol. Chem. 276: 48967-48972.
28. STITT, A. et al. 2002. The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes. Diabetes 51: 2826-2832.
29. WELLS-KNECHT, K.J. et al. 1995. Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose. Biochemistry 34: 3702-3709.
30. FU, M.X. et al. 1996. The advanced glycation end product, Nepsilon-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271: 9982-9986.
31. ANDERSON, M.M., S.L. HAZEN, F.F. HSU & J.W. HEINECKE. 1997. Human neutrophils employ the myeloperoxidase-hydrogen peroxide-chloride system to convert hydroxyamino acids into glycolaldehyde, 2-hydroxypropanal, and acrolein. A mechanism for the generation of highly reactive alpha-hydroxy and alpha,beta-unsaturated aldehydes by phagocytes at sites of inflammation. J. Clin. Invest. 99: 424-432.
32. THORPE, S.R. & J.W. BAYNES. 2003. Maillard reaction products in tissue proteins: new products and new perspectives. Amino Acids 25: 275-281.
33. ONORATO, J.M., A.J. JENKINS, S.R. THORPE & J.W. BAYNES. 2000. Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. Mechanism of action of pyridoxamine. J. Biol. Chem. 275: 21177-21184.
34. VOZIYAN, P.A., T.O. METZ, J.W. BAYNES & B.G. HUDSON. 2002. A post-Amadori inhibitor pyridoxamine also inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J. Biol. Chem. 277: 3397-3403.
35. NAGARAJ, R.H. et al. 2002. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. Arch. Biochem. Biophys. 402: 110-119.
36. AMARNATH, V. et al. 2004. Pyridoxamine: an extremely potent scavenger of 1,4-dicarbonyls. Chem. Res. Toxicol. 17: 410-415.
37. IACOVELLA, G. et al. 2003. Pyridoxamine decreases levels of reactive alpha-dicarbonyls in plasma of ZDF diabetic rats (Abstr.). Diabetes 52(Suppl. 1): A187-A187.
38. ALDERSON, N.L. et al. 2003. The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats. Kidney Int. 63: 2123-2133.
39. METZ, T.O. et al. 2003. Pyridoxamine traps intermediates in lipid peroxidation reactions in vivo: evidence on the role of lipids in chemical modification of protein and development of diabetic complications. J. Biol. Chem. 278: 42012-42019.
40. SHIMOI, K. et al. 2001. Oxidative DNA damage induced by high glucose and its suppression in human umbilical vein endothelial cells. Mutat. Res. 480-481: 371-378.
41. ZHENG, F. et al. 2002. Reduction of glomerular lesions and albuminuria in db/db mice with established diabetic nephropathy following pyridoxamine treatment (Abstr.). J. Am. Soc. Nephrol. 13: 534A-535A.
42. CAMERON, N. et al. 2003. Pyridoxamine treatment improves nerve function in diabetic rats (Abstr.). Diabetes 52: A192.
43. METZ, T.O., N.L. ALDERSON, S.R. THORPE & J.W. BAYNES. 2003. Pyridoxamine, an inhibitor of advanced glycation and lipoxidation reactions: a novel therapy for treatment of diabetic complications. Arch. Biochem. Biophys. 419: 41-49.
44. DROGE, W. 2003. Oxidative stress and aging. Adv. Exp. Med. Biol. 543: 191-200.
45. MIKKELSEN, R.B. & P. WARDMAN. 2003. Biological chemistry of reactive oxygen and nitrogen and radiation-induced signal transduction mechanisms. Oncogene 22: 5734-5754.
46. TAKANO, H. et al. 2003. Oxidative stress-induced signal transduction pathways in cardiac myocytes: involvement of ROS in heart diseases. Antioxid. Redox. Signal. 5: 789-794.
47. BROWNLEE, M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
48. SMITH, P.R. & P.J. THORNALLEY. 1992. Mechanism of the degradation of non-enzymatically glycated proteins under physiological conditions. Studies with the model fructosamine, N epsilon-(1-deoxy-D-fructos-1-yl)hippuryl-lysine. Eur. J. Biochem. 210: 729-739.
49. MOSSINE, V.V. et al. 1999. Superoxide free radical generation by Amadori compounds: the role of acyclic forms and metal ions. Chem. Res. Toxicol. 12: 230-236.
50. MIYATA, T. et al. 2002. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J. Am. Soc. Nephrol. 13: 2478-2487.
51. DAUMER, K.M., A.U. KHAN & M.J. STEINBECK. 2000. Chlorination of pyridinium compounds. Possible role of hypochlorite, N-chloramines, and chlorine in the oxidation of pyridinoline cross-links of articular cartilage collagen type II during acute inflammation. J. Biol. Chem. 275: 34681-34692.
52. JAIN, S.K. & G. LIM. 2001. Pyridoxine and pyridoxamine inhibits superoxide radicals and prevents lipid peroxidation, protein glycosylation, and (Na+ + K+)-ATPase activity reduction in high glucose-treated human erythrocytes. Free Radic. Biol. Med. 30: 232-237.
53. CAHUANA, G.M. et al. 2004. Nitric oxide-induced carbonylation of Bcl-2, GAPDH and ANT precedes apoptotic events in insulin-secreting RINm5F cells. Exp. Cell Res. 293: 22-30.
54. TAKATORI, A. et al. 2004. Amelioration of the beta-cell dysfunction in diabetic APA hamsters by antioxidants and AGE inhibitor treatments. Diabetes Metab. Res. Rev. 20: 211-218.
55. MENON, M. & H. KOUL. 1992. Clinical review 32: Calcium oxalate nephrolithiasis. J. Clin. Endocrinol. Metab. 74: 703-707.
56. ROBERTSON, W.G. & M. PEACOCK. 1980. The cause of idiopathic calcium stone disease: hypercalciuria or hyperoxaluria? Nephron 26: 105-110.
57. HOLMES, R.P. & D.G. ASSIMOS. 1998. Glyoxylate synthesis, and its modulation and influence on oxalate synthesis. J. Urol. 160: 1617-1624.
58. CHETYRKIN, S. et al. 2005. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Kidney Int. 67: 53-60.
59. CHETYRKIN, S. et al. 2002. A new method for treatment of hyperoxaluria and kidney stone disease (Abstr.). J. Am. Soc. Nephrol. 13: 574A.
60. CHETYRKIN, S. et al. 2003. A new method for treatment of hyperoxaluria and kidney stone disease: pyridoxamine inhibits kidney crystal formation in hyperoxaluric rats (Abstr.). J. Am. Soc. Nephrol. 14: 701A.
61. DEGENHARDT, T.P. et al. 2002. Pharmacokinetics, tolerability and biologic activity of oral Pyridorin, a novel AGE inhibitor, in patients with type 1 diabetes and diabetic nephropathy (Abstr.). J. Am. Soc. Nephrol. 13: 652A.
62. WILLIAMS, M.E. et al. 2003. A phase 2 clinical trial of pyridoxamine (Pyridorin) in type 1 and type 2 diabetic patients with overt nephropathy (PYR-206) (Abstr.). J. Am. Soc. Nephrol. 14: 7A.
63. KHALIFAH, R.G., et al. 2002. Mechanism of action of Pyridorin (pyridoxamine), a novel therapeutic for diabetic complications (Abstr.). J. Am. Soc. Nephrol. 13: 535A.
64. CULBERTSON, S.M., G.D. ENRIGHT & K.U. INGOLD. 2003. Synthesis of a novel radical trapping and carbonyl group trapping anti-AGE agent: a pyridoxamine analogue for inhibiting advanced glycation (AGE) and lipoxidation (ALE) end products. Org. Lett. 5: 2659-2662.
65. CULBERTSON, S.M., E.I. VASSILENKO, L.D. MORRISON & K.U. INGOLD. 2003. Paradoxical impact of antioxidants on post-Amadori glycoxidation: counterintuitive increase in the yields of pentosidine and N(ε)- carboxymethyllysine using a novel multifunctional pyridoxamine derivative. J. Biol. Chem. 278: 38384-38394.
66. BAYNES, J.W. & S.R. THORPE. 2000. Glycoxidation and lipoxidation in atherogenesis. Free Radic. Biol. Med. 28: 1708-1716.
67. DUKIC-STEFANOVIC, S. et al. 2001. AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs? Biogerontology 2: 19-34.
68. BAYNES, J.W. 2002. The Maillard hypothesis on aging: time to focus on DNA. Ann. N.Y. Acad. Sci. 959: 360-367.